FDA Roundup: November 17, 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
FDA approves DefenCath for adults with kidney failure on chronic hemodialysis healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Analysts’ updated eps estimates for Wednesday, November 15th: Babcock International Group (LON:BAB) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a GBX 550 ($6.75) target price on the stock. British American Tobacco (LON:BATS) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. […]
CorMedix Inc. (CRMD) shares are surging more than 34 percent on Wednesday morning trade after the company said it is targeting a commercial launch of DefenCath before the end of the first quarter of 2024, if it receives final FDA approval.